• Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact

Barry A. Friedman, PhD LLC

FDA Regulatory Compliance for the Pharmaceutical, Biotechnology and Medical Device Arenas

H and P Industries Lawsuit Ties Tainted Wipes to Twin’s Brain Damage

July 11, 2011 By Barry Friedman 1 Comment

MSNBC Reports On On-Going Rare Bacterial Infection Stumped Experts Until News Of Contaminated Products Surfaced For nearly four years, a bacterial infection that left a Seattle-area newborn with severe brain damage while his twin brother developed normally has remained a medical mystery, traumatizing his family and stumping local and national disease experts. Myles Massey, … [Read more...]

Indian Mexican API Facilities Cited by FDA in Warning Letter

July 6, 2011 By Barry Friedman Leave a Comment

 Dr. Reddy's Laboratories Found in Non-Compliance and In Receipt of an Import Ban  Comment  Dr Reddy's Mexico facilities were inspected between November 8-11, 2010.  During the audit the FDA identified significant deviations from CGMP for the manufacture of APIs.  These deviations caused the APIs to be adulterated.  A response dated December 1, 2010, received by the Agency, … [Read more...]

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

June 27, 2011 By Barry Friedman Leave a Comment

CDER NAMES THESE TEN (21 CFR 211) Comment The following represent those most frequent Observations that CDER posted for fiscal year 2010 based on a total of 646 FDA Form 483.  REFERENCE              … [Read more...]

TOP 15 BACTERIA REPRESENT 50% OF BACTERIAL ISOLATES IDENTIFIED

June 22, 2011 By Barry Friedman Leave a Comment

ACCUGENIX IDENTIFIED WHAT MICROORGANISMS REPRESENT THE OTHER 50% While having knowledge of the most frequently identified bacteria is informative, it is important to note that these Top 15 bacteria identified from manufacturing environments, as cited in the original post, only represent approximately 50% of the microbes that are identified during routine monitoring and … [Read more...]

FDA ENTERS CONSENT DECREE WITH H AND P INDUSTRIES (TRIAD GROUP)

June 14, 2011 By Barry Friedman 1 Comment

TRIAD GROUP MUST AWAIT AN ACCEPTABLE QUALITY ASSURANCE AND QUALITY CONTROL PROGRAM BEFORE RESUMING MANUFACTURING AND DISTRIBUTION Comment The FDA entered into a Consent Decree of Condemnation, Forfeiture and Permanent Injunction against H&P Industries that would prevent them from manufacturing and distributing products from their Hartland, WI facility.  Under the decree, … [Read more...]

« Previous Page
Next Page »
New Reader? Learn More

Connect With Me:

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Webinar Registration & Information

FREQUENTLY ASKED QUESTIONS:

FDA Form 483 Frequently Asked Questions

USP General Chapter

USP General Chapter 62, Part II

TOP OBSERVATIONS:

FDA’s CDER LISTING OF TOP NINETEEN OBSERVATIONS FOR 2014

FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

Top Posts:

Top Posts for 2012

Top Posts for 2013

Top Posts Year To Date

Recent Posts

  • Upcoming Microbiological Webinars
  • Microbiological Webinars
  • Microbiological Webinars 2020 (Upcoming)
  • General Chapter (USP<60>) on B. cepacia Complex to Issue December 1, 2019
  • Les Produits Chimiques B.G.R., Inc. Receives FDA Warning Letter (07/24/2018) for Failure to Perform Laboratory Testing

Categories

follow us in feedly
  • Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Thank You For Visiting Barry A. Friedman, PhD LLC - 2015

Welcome To My Blog!
Please enter your name and email below to receive my newsletter.
Your information will *never* be shared or sold to a 3rd party.